New drug combo targets tough ovarian cancers
NCT ID NCT07593092
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This early-stage trial tests two experimental drugs, XmAb541 and XmAb808, in people with advanced ovarian cancer that has come back or spread. The main goal is to see if the combination is safe and find the best dose. About 90 adults with a specific tumor marker (CLDN6) will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE SEROUS OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Xencor Investigative Site
RECRUITINGLake Success, New York, 11042, United States
-
Xencor Investigative Site
RECRUITINGNew York, New York, 10029, United States
-
Xencor Investigative Site
RECRUITINGThe Bronx, New York, 10461, United States
-
Xencor Investigative Site
RECRUITINGFort Worth, Texas, 76104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?